Elorac, Inc. specializes in the development of innovative pharmaceuticals specifically tailored for the dermatology market. The company is committed to advancing the science of skin care through the discovery and development of first-in-class therapies aimed at addressing various skin conditions. Their focus on the needs of patients and the expertise of experienced healthcare professionals underscores their dedication to finding new treatments in medical dermatology.

One of the key initiatives currently underway at Elorac is a clinical trial involving Naloxone Hydrochloride, which is being studied for its effectiveness in relieving pruritus in patients with Mycosis Fungoides, a form of cutaneous T-cell lymphoma (CTCL). This trial is actively recruiting participants, highlighting Elorac's commitment to advancing treatment options for patients suffering from complex dermatological conditions. For more details on the study, interested individuals can refer to ClinicalTrials.gov.

United States

Elorac, Inc. is a specialty pharmaceutical company devoted to developing, commercializing, and marketing dermatology products.  Elorac has over 20 novel prescription products in development.  Our products embody proprietary technologies or compounds, all protected by patents or covered by proprietary technology.

Cancer

Hematologic Diseases

Infectious Diseases

Lymphatic Diseases

Elorac, Inc

Mycosis fungoides

Sezary syndrome

T-cell lymphoma

Naloxone Hydrochloride Lotion, 0.5%

Biologics

Illinois

Repurposed/505(b)(2) Drugs

Small Molecule Pharmaceuticals

Therapeutic

Elorac, Inc

Company Details